Sermorelin + PT-141 (Bremelanotide) Stack: Complete Protocol for Women

What These Two Peptides Actually Do

These are two distinct peptides operating on two entirely different biological targets. Understanding that separation is the foundation for understanding why the stack can make sense.

Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), specifically the first 29 amino acids of endogenous GHRH. When injected, it binds GHRH receptors in the anterior pituitary and prompts your own pituitary to release growth hormone in a physiologic, pulsatile pattern. Natural GH secretion is highest during slow-wave sleep, which is why sermorelin is almost universally dosed at bedtime. GH levels decline roughly 14% per decade after age 30, a process called somatopause, and this decline tracks closely with changes in body composition, sleep quality, and energy that many women first notice in their late 30s and into perimenopause.

PT-141, the trade name for bremelanotide, does something completely different. It is a cyclic heptapeptide melanocortin agonist that binds MC3R and MC4R receptors in the hypothalamus and limbic system. It does not act peripherally on genitalia or blood vessels. Instead, it modulates the central neurological circuits that generate sexual desire. This central mechanism is why the FDA approved bremelanotide (Vyleesi) in June 2019 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the only on-demand pharmacological option for HSDD.

Why Women Consider Both at Once

The overlap is not arbitrary. As estrogen and progesterone shift during perimenopause, GH pulsatility decreases, lean mass drops, central adiposity increases, and sexual desire often falls. These changes share neuroendocrine roots. A woman in her mid-40s dealing with unexplained fatigue, body composition changes, and flat libido may have interconnected hormonal deficits that a single-target approach does not address.

These are two separate clinical problems. Prescribers who combine them are not treating a single condition. They are treating two conditions in one protocol.

How the Two Mechanisms Interact (or Don't)

Receptor-Level Independence

Sermorelin binds GHRH receptors. PT-141 binds melanocortin receptors. There is no shared receptor family, no known competitive binding, and no pharmacokinetic interaction. Melanocortin receptor signaling in the hypothalamus does intersect with GH-axis regulation at a systems level, meaning MC4R activation may modestly influence GH pulse amplitude, but this cross-talk has not been studied in humans at clinical doses.

Pharmacokinetic Separation

Sermorelin has a plasma half-life of approximately 10-20 minutes, though its downstream GH pulse lasts 1-3 hours. PT-141 has a longer half-life of roughly 2.7 hours with peak effect on desire emerging at 45-60 minutes post-injection and lasting up to 12 hours in some women. Because sermorelin is dosed at bedtime and PT-141 is dosed pre-activity (typically mid-evening or earlier), the two are rarely pharmacologically active simultaneously, which further limits interaction risk.

The Evidence Gap (Be Honest About This)

No randomized controlled trial has tested sermorelin and PT-141 together. The combination rationale comes from:

1. Mechanistic plausibility (independent receptor pathways, no known interaction)
2. Animal studies showing GH and melanocortin axes respond independently to their respective agonists
3. Practitioner-reported outcomes in compounding pharmacy-based programs
4. Extrapolation from each peptide's individual safety and efficacy data

This evidence hierarchy matters. You can reasonably infer that co-administration is unlikely to create pharmacological harm. You cannot infer that the combination produces synergistic benefit beyond what each peptide does alone, because no controlled data exists to show that.

Sex-Specific Physiology: What Changes for Women

GH Axis Differences in Women

Women already have higher baseline GH pulse amplitude than age-matched men, driven partly by estrogen's sensitizing effect on GH receptors. Estradiol increases GH pulse amplitude and IGF-1 response to GHRH. This means that as estrogen declines in perimenopause and postmenopause, the GH axis loses an important amplifying signal. Sermorelin may therefore produce a more pronounced response in estrogen-replete women (reproductive years, or postmenopausal women on estrogen therapy) compared to estrogen-depleted postmenopausal women off HRT.

Practically: if you are postmenopausal and not on hormone therapy, sermorelin's IGF-1 response may be blunted compared to what clinical reports in younger women suggest. Dose adjustments may be needed, though no female-specific dose-ranging trial exists.

Menstrual Cycle Variability

GH pulsatility fluctuates across the menstrual cycle. GH secretion is highest in the late follicular and periovulatory phases when estradiol peaks. If you are tracking IGF-1 levels on sermorelin, testing in the early follicular phase (days 2-5) gives the most reproducible baseline, avoiding the natural midcycle peak.

PT-141 in Women: What the Trials Actually Show

The RECONNECT trials, two Phase 3 randomized, placebo-controlled studies, enrolled premenopausal women with HSDD and demonstrated that 1.75 mg bremelanotide increased satisfying sexual events by approximately 0.5 events per month and decreased distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) by 11.1 points versus 8.0 points for placebo. The effect size is moderate, not dramatic, and the trials required sexual activity on at least two occasions per month to capture endpoints. Women in these trials were required to be premenopausal.

Postmenopausal use is extrapolated from pharmacokinetic and mechanistic data. The FDA label does not include postmenopausal women in its approved indication. A clinician choosing to prescribe PT-141 to a postmenopausal woman is using it off-label, and the absence of dedicated RCT data in that population is a genuine limitation you should discuss with your provider.

Complete Dosing Protocol

Sermorelin Dosing for Women

| Parameter | Detail | |---|---| | Starting dose | 200-300 mcg subcutaneous nightly | | Typical maintenance | 300-500 mcg nightly | | Timing | 30-60 minutes before sleep, fasted (no food 2 hours prior) | | Injection site | Abdomen or lateral thigh, subcutaneous | | Monitoring | Baseline and 8-12 week IGF-1; fasting glucose; fasting insulin | | Cycle | Many clinicians use 5 days on, 2 days off to preserve pituitary sensitivity |

Food blunts GH pulse. A high-carbohydrate meal raises somatostatin, which suppresses GH release, so the bedtime dose must be given fasted or your pituitary response will be diminished regardless of dose.

PT-141 Dosing for Women

The FDA-approved dose is 1.75 mg subcutaneous no more than once per 24 hours and no more than once per 8 weeks based on the label, though clinical practice typically allows more frequent use off-label. The label restricts use to 8 per month maximum. Most prescribers start at 1.25 mg to assess tolerability, particularly nausea.

| Parameter | Detail | |---|---| | Starting dose | 1.25 mg subcutaneous (assess nausea tolerance first) | | Full dose | 1.75 mg subcutaneous | | Timing | 45-60 minutes before anticipated sexual activity | | Injection site | Abdomen, subcutaneous | | Frequency | No more than once in 24 hours; FDA label: max ~8 uses/month | | Duration of effect | Desire enhancement can last up to 12 hours |

Combined Stack Timing (a Practical Schedule)

Because sermorelin is a bedtime dose and PT-141 is a pre-activity dose, they rarely overlap pharmacologically on the same evening. On a night when you use PT-141:

• 6:00-8:00 PM: PT-141 1.25-1.75 mg subcutaneous
• 10:00-11:00 PM: Sermorelin 300-500 mcg subcutaneous (after activity, fasted before sleep)

If sexual activity happens to fall late in the evening immediately before bedtime, you may choose to give PT-141 and forgo sermorelin that night to keep the administration simple. Missing one dose of sermorelin on an occasional basis does not affect the overall GH-axis response, which accrues over weeks and months.

Who This Stack Is Right For (and Who It Is Not)

Women Who May Benefit

• Perimenopausal women (ages 40-55) experiencing a combination of declining energy, body composition changes, and reduced libido with no single-hormone explanation
• Women with confirmed low IGF-1 on labs (below 100-150 ng/mL in a mid-reproductive-age woman) who have ruled out pituitary pathology
• Premenopausal women with documented HSDD (as defined by DSM-5 criteria: persistent low desire causing personal distress, not explained by relationship or medication)
• Women already on HRT who have optimized estrogen/progesterone but still report flat libido and poor body composition

Women Who Should Not Use This Stack

• Anyone pregnant or actively trying to conceive. Both peptides are contraindicated in pregnancy. See the full section below.
• Women with active or prior melanoma or other melanocytic tumors: MC4R agonism causes transient hyperpigmentation and may theoretically stimulate melanocytes. PT-141 prescribers consistently exclude this population.
• Women with uncontrolled hypertension: bremelanotide transiently raises blood pressure by an average of 2-4 mmHg systolic and approximately 1-2 mmHg diastolic, which is clinically significant if baseline blood pressure is already elevated.
• Women with active pituitary tumors or hypothalamic disease: sermorelin stimulates the pituitary and requires an intact, functional axis.
• Women with cardiovascular disease or arrhythmias: pulsatile GH release transiently affects insulin sensitivity and fluid balance; cardiac patients need cardiologist clearance before any GH-axis therapy.
• Adolescents and women under 18: neither peptide has safety data in this population.

Pregnancy, Lactation, and Contraception

Both sermorelin and PT-141 (bremelanotide) are contraindicated during pregnancy. This is not a gray-area caution. This is a hard stop.

Bremelanotide (PT-141) in Pregnancy

The FDA label for Vyleesi explicitly states that bremelanotide is contraindicated in pregnancy and that women should discontinue use if pregnancy occurs. Animal reproductive toxicology studies showed embryo-fetal lethality and reduced fetal weight at doses above the clinical dose. Human data does not exist, because the drug is not to be used in pregnancy. The label requires that women of reproductive potential use effective contraception.

If you have any chance of being pregnant on the day you plan to use PT-141, do not use it. Take a pregnancy test first if there is any uncertainty.

Sermorelin in Pregnancy

Sermorelin's FDA approval is as a diagnostic agent for GH deficiency evaluation. There is no FDA pregnancy category assigned under the modern labeling system, and no human pregnancy safety data exists for sermorelin used long-term. GH-axis stimulation during pregnancy is theoretically problematic: GH and IGF-1 regulation shifts dramatically in pregnancy, with placental GH replacing pituitary GH as the dominant isoform by the second trimester. Stimulating pituitary GH output with sermorelin on top of placental GH represents an uncharacterized and potentially harmful hormonal imbalance.

No compounding pharmacy or prescriber should initiate sermorelin in a pregnant woman. If you become pregnant while using sermorelin, stop immediately and inform your obstetric provider.

Lactation

Neither sermorelin nor bremelanotide has human lactation data. Both are peptides that would likely be degraded in the infant GI tract if transferred via breast milk, making systemic infant exposure theoretically low, but the absence of lactation data means neither can be considered safe during breastfeeding. Clinicians following standard precautionary principles do not prescribe either peptide to breastfeeding women.

Contraception Requirement

If you are of reproductive age and are prescribed PT-141, your prescriber should confirm you are using reliable contraception. The same applies to sermorelin when used off-label long-term. Barrier methods, hormonal contraception, or an IUD all qualify. Fertility-awareness methods alone are generally considered insufficient given the risks.

Side Effects and How They Differ by Life Stage

Sermorelin Side Effects

• Injection site reactions (most common): redness, transient pain, small nodules
• Transient water retention or facial flushing in the first weeks as GH rises
• Headache (usually resolves within 2-4 weeks)
• Potential worsening of insulin resistance at higher doses: supraphysiologic GH elevates fasting glucose and this warrants monitoring in women with PCOS or pre-diabetes, two conditions with already elevated insulin-resistance risk
• Women with PCOS should be monitored especially carefully because GH-axis abnormalities are common in PCOS and adding exogenous GH-axis stimulation may alter androgen levels and IGF-1 in unpredictable directions

PT-141 Side Effects

• Nausea: the most commonly reported side effect, affecting approximately 40% of women in the RECONNECT trials at the 1.75 mg dose. Starting at 1.25 mg substantially reduces nausea frequency.
• Transient hyperpigmentation: MC4R agonism activates melanocytes. Most women notice this as mild darkening of pre-existing moles or skin in injection areas. This reverses after discontinuation but should be monitored.
• Transient blood pressure elevation: 2-4 mmHg systolic on average, peaking at about 1 hour post-dose. Check your blood pressure before and 90 minutes after your first dose.
• Flushing: common and usually mild, lasting 1-2 hours.
• Fatigue on the day of use: reported by some women, particularly at higher doses.

Postmenopausal women may be more sensitive to the blood pressure effects given that hypertension prevalence rises sharply after menopause. Check baseline blood pressure before starting.

Monitoring Labs and Follow-Up

A responsible protocol includes lab monitoring, not just symptom tracking.

| Lab | Timing | Why | |---|---|---| | IGF-1 (serum) | Baseline, then at 8-12 weeks | Confirm sermorelin response; stay within age-appropriate reference range | | Fasting glucose | Baseline, then at 8-12 weeks | GH reduces insulin sensitivity | | Fasting insulin | Baseline, then at 8-12 weeks | Early insulin-resistance signal | | HbA1c | Baseline in women with PCOS or pre-diabetes | Detect glycemic drift | | Blood pressure | Day 1 post-PT-141 (first dose) | Detect hypertensive response | | Thyroid panel (TSH, free T4) | Baseline | GH therapy can unmask central hypothyroidism | | LH, FSH, estradiol | As clinically indicated | Confirm hormonal context, especially if perimenopausal |

Target IGF-1 on sermorelin: most compounding-focused clinicians aim for the upper half of the age-appropriate reference range, not above the upper limit. Supra-normal IGF-1 is associated with increased insulin-like growth factor signaling and theoretical cancer risk in long-term observational data.

The Conditions This Stack Touches in Women

PCOS

Women with PCOS have altered GH-axis dynamics, often with lower GH pulse amplitude but elevated IGF-1 in some subtypes, and frequently have HSDD due to hormonal imbalance, androgenic acne treatments, or relationship distress from the condition itself. Sermorelin in PCOS is an off-label, poorly-studied application. IGF-1 and androgen monitoring is especially important.

Perimenopause

This is the most clinically coherent target population for this stack. Estrogen fluctuation simultaneously suppresses the GH axis and disrupts central desire circuits. Women in perimenopause who are not good candidates for or not interested in full HRT sometimes explore peptide protocols as an adjunct. They should still understand that HRT has decades of data and this stack does not.

Postpartum

Neither peptide should be used postpartum while breastfeeding. Postpartum HSDD is common and often multifactorial (prolactin elevation, estrogen suppression, sleep deprivation, relationship stress). PT-141 is not the right first tool in this setting. The postpartum period warrants its own clinical evaluation before any peptide protocol is considered.

Hypothyroidism and Thyroid Disease

GH therapy can reduce conversion of T4 to T3 by upregulating type 3 deiodinase, and sermorelin-driven GH elevation may do the same. Women with existing hypothyroidism on levothyroxine may see a temporary rise in TSH after starting sermorelin and may need a dose adjustment. Thyroid function should be checked at baseline and after 8-12 weeks.

What "Off-Label" and "Compounded" Mean for Your Safety

Sermorelin as a long-term body composition or anti-aging peptide is off-label use. PT-141 at doses other than 1.75 mg, or more frequently than the label allows, is also off-label. Compounded sermorelin is not FDA-approved as a formulation; it is prepared by 503A or 503B compounding pharmacies under rules that do not include the same batch-testing requirements as commercial manufacturing.

This does not make the compounds inherently unsafe, but it does mean the quality, sterility, and concentration depend on the pharmacy's compliance practices. The FDA has issued guidance on compounded drugs used in weight management and related conditions that clarifies what compounders can and cannot do. Ask your prescriber which pharmacy they use and whether it is PCAB-accredited.

What We Don't Know (The Evidence Gap, Named Clearly)

Women have been consistently underrepresented in peptide research. The sermorelin literature comes primarily from studies in men with adult GH deficiency or from pediatric growth studies. The PT-141 literature, while it does include women (the RECONNECT trials enrolled women only for the HSDD indication), did not study long-term use beyond the trial period, did not study women over 50 systematically, and did not study combination use with other peptides.

What is extrapolated, not directly studied, for women:

• Optimal sermorelin dosing for perimenopausal and postmenopausal women
• IGF-1 target ranges by hormonal status (estrogen-replete vs. Depleted)
• Long-term PT-141 safety at frequencies exceeding the FDA label
• Any outcomes data for the sermorelin and PT-141 combination specifically
• Effect of the stack on menstrual cycle regularity

Honesty about these gaps is not a reason to avoid all clinical use. It is a reason to use the lowest effective doses, monitor labs, and revisit the decision with your provider every 6-12 months.